Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Bright Minds Biosciences ( (TSE:DRUG) ) has shared an update.
On January 6, 2026, Bright Minds Biosciences reported positive topline results from its Phase 2 BREAKTHROUGH trial of BMB-101 in adults with drug‑resistant absence seizures and developmental and encephalopathic epilepsies. The open-label study, which enrolled 24 heavily pre-treated patients across both cohorts, met its primary efficacy endpoints, showing a 73.1% median reduction in absence seizures lasting at least three seconds and a 63.3% median reduction in major motor seizures in DEE patients, alongside a favorable safety profile with mostly mild or moderate adverse events and no treatment-related serious events. Investigators also observed a substantial 90% increase in REM sleep without extending total sleep duration, suggesting potential cognitive and behavioral benefits beyond seizure control. On the back of these results, the company has begun preparations for global registrational trials in both indications and plans to launch a Prader-Willi syndrome study in the first quarter of 2026, signaling an effort to advance BMB-101 toward late-stage development and expand its footprint in rare, drug-resistant neurological disorders.
The most recent analyst rating on (TSE:DRUG) stock is a Buy with a C$101.00 price target. To see the full list of analyst forecasts on Bright Minds Biosciences stock, see the TSE:DRUG Stock Forecast page.
Spark’s Take on TSE:DRUG Stock
According to Spark, TipRanks’ AI Analyst, TSE:DRUG is a Neutral.
The score is primarily constrained by weak financial performance driven by a pre-revenue model, recurring losses, and negative free cash flow despite a strong low-debt balance sheet. Technicals are mixed but modestly supportive over the medium term, while valuation remains challenged by negative earnings and no dividend yield data.
To see Spark’s full report on TSE:DRUG stock, click here.
More about Bright Minds Biosciences
Bright Minds Biosciences Inc. is a clinical-stage biotechnology company developing highly selective 5-HT receptor agonists for neurological and psychiatric disorders. Listed on the CSE and Nasdaq under the ticker DRUG, the company is focused on drug candidates such as BMB-101, a selective 5-HT2C biased agonist, targeting treatment-resistant seizure disorders including absence seizures and developmental and encephalopathic epilepsies (DEE).
Average Trading Volume: 1,244
Technical Sentiment Signal: Buy
Current Market Cap: C$809.9M
For detailed information about DRUG stock, go to TipRanks’ Stock Analysis page.